Image: StatnewsModerna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
• Moderna and Merck announced that a personalized mRNA cancer vaccine successfully slowed the recurrence and spread of melanoma in a late-stage clinical trial. • The vaccine was administered in combination with Merck's immunotherapy drug, Keytruda, to enhance the body's immune response against the cancer. • This result is significant as it demonstrates the potential for mRNA technology to be adapted for oncology, moving beyond its success in COVID-19 vaccinations.
statnews.com
